Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)
DOI:
https://doi.org/10.33393/grhta.2025.3199Keywords:
Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), Decision-making, Multi-criteria Decision Analysis (MCDA), Ultra-rare disease, leniolisibAbstract
Background: Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS) is an ultra-rare, potentially life-threatening disease that lacks approved treatments in Spain. This study aimed to apply Multi-Criteria Decision Analysis (MCDA) to assess the value of the first pharmacological treatment for APDS in Spain.
Methods: A multidisciplinary group of 8 experts evaluated the selective PI3Kδ inhibitor leniolisib against Standard of Care (SoC). An MCDA framework tailored for Orphan Drugs (ODs), consisting of 5 comparative and 2 quantitative non-comparative criteria, was used. Re-scoring followed a group discussion.
Results: Leniolisib scored higher than SoC in all criteria, including efficacy and safety. It was deemed highly valuable as the first disease-modifying treatment, with a positive therapeutic impact and potential to improve patients’ quality of life. Additionally, leniolisib may lead to cost savings. The supporting data was considered of high quality.
Conclusion: Based on MCDA methodology and stakeholder experience in APDS management, leniolisib is seen as a value-added treatment option compared to SoC in Spain.
Downloads
References
Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. 2014;342(6160):866–71.https://pubmed.ncbi.nlm.nih.gov/24136356/
Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88-97. DOI: https://doi.org/10.1038/ni.2771 PMID:24165795 DOI: https://doi.org/10.1038/ni.2771
Lucas CL, Zhang Y, Venida A, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211(13):2537-2547. DOI: https://doi.org/10.1084/jem.20141759 PMID:25488983 DOI: https://doi.org/10.1084/jem.20141759
Deau MC, Heurtier L, Frange P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124(9):3923-3928. DOI: https://doi.org/10.1172/JCI75746 PMID:25133428 DOI: https://doi.org/10.1172/JCI75746
Orphanet: Síndrome de PI3K delta activado. Online (Accessed July 2024) https://www.orpha.net/es/disease/detail/397596
Goetghebeur MM, Wagner M, Khoury H, et al. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Making. 2012;32(2):376-388. DOI: https://doi.org/10.1177/0272989X11416870 PMID:21987539 DOI: https://doi.org/10.1177/0272989X11416870
Frazão TDC, Camilo DGG, Cabral ELS, Souza RP. Multicriteria decision analysis (MCDA) in health care: A systematic review of the main characteristics and methodological steps. Vol 18. BMC Medical Informatics and Decision Making. BioMed Central Ltd; 2018.https://pubmed.ncbi.nlm.nih.gov/30382826/ DOI: https://doi.org/10.1186/s12911-018-0663-1
Abad MR, Alerany C, Alsina L, et al. Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders. Glob Reg Health Technol Assess. 2024;11(1):124-130.. DOI: https://doi.org/10.33393/grhta.2024.3041 PMID:38784663 DOI: https://doi.org/10.33393/grhta.2024.3041
Maccari ME, Wolkewitz M, Schwab C, et al; European Society for Immunodeficiencies Registry Working Party. Activated phosphoinositide 3-kinase δ syndrome: update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol. 2023;152(4):984-996.e10. DOI: https://doi.org/10.1016/j.jaci.2023.06.015 PMID:37390899 DOI: https://doi.org/10.1016/j.jaci.2023.06.015
Kumar BV, Connors TJ, Farber DL. Human T Cell Development, Localization, and Function throughout Life. Immunity. 2018;48(2):202-213. DOI: https://doi.org/10.1016/j.immuni.2018.01.007 PMID:29466753 DOI: https://doi.org/10.1016/j.immuni.2018.01.007
Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study. J Allergy Clin Immunol. 2016;138(1):210-218.e9. DOI: https://doi.org/10.1016/j.jaci.2016.03.022 PMID:27221134 DOI: https://doi.org/10.1016/j.jaci.2016.03.022
Hoegenauer K, Soldermann N, Zécri F, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017;8(9):975-980. DOI: https://doi.org/10.1021/acsmedchemlett.7b00293 PMID:28947947 DOI: https://doi.org/10.1021/acsmedchemlett.7b00293
Rao VK, Webster S, Dalm VASH, et al. Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood. 2017;130(21):2307-2316. DOI: https://doi.org/10.1182/blood-2017-08-801191 PMID:28972011 DOI: https://doi.org/10.1182/blood-2017-08-801191
Fruman DA, Chiu H, Hopkins BD, et al. The PI3K Pathway in Human Disease. Cell. 2017;170(4):605-635. DOI: https://doi.org/10.1016/j.cell.2017.07.029 PMID:28802037 DOI: https://doi.org/10.1016/j.cell.2017.07.029
Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317-330. DOI: https://doi.org/10.1038/nri1056 PMID:12669022 DOI: https://doi.org/10.1038/nri1056
Food and Drug Administration. Leniolisib prescribing information. Online https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-activated-phosphoinositide-3-kinase-delta-syndrome#:~:text=FDA%20has%20approved%20Joenja%20%28leniolisib%29%20tablets%20as%20the,mg%20orally%20twice%20a%20day%2C%20approximately%2012%E2%80%AFhours%20apart (Accessed July 2024)
European Medicines Agency (EMA). Online https://www.ema.europa.eu/en/homepage (Accessed July 2024)
Marsh K, IJzerman M, Thokala P, et al; ISPOR Task Force. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(2):125-137. DOI: https://doi.org/10.1016/j.jval.2015.12.016 PMID:27021745 DOI: https://doi.org/10.1016/j.jval.2015.12.016
Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making - An introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(1):1-13. DOI: https://doi.org/10.1016/j.jval.2015.12.003 PMID:26797229 DOI: https://doi.org/10.1016/j.jval.2015.12.003
Badia X, Chugani D, Abad MR, et al. Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain. Vol. 7. Expert Opin Orphan Drugs. 2019;7(7-8):363-372. DOI: https://doi.org/10.1080/21678707.2019.1652163 DOI: https://doi.org/10.1080/21678707.2019.1652163
Badia X, Calleja M, Mirco A, et al. HT6 - DO SPAIN AND PORTUGAL EVALUATORS AND DECISION MAKERS GIVE THE SAME IMPORTANCE TO EVALUATION CRITERIA OF INNOVATIVE MEDICINES? Value Health. 2018;21:S9. DOI: https://doi.org/10.1016/j.jval.2018.09.052 DOI: https://doi.org/10.1016/j.jval.2018.09.052
Gilabert-Perramon A, Torrent-Farnell J, Catalan A, et al. DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS. Int J Technol Assess Health Care. 2017;33(1):111-120. Accessed December 18, 2023. DOI: https://doi.org/10.1017/S0266462317000149 PMID:28434413 DOI: https://doi.org/10.1017/S0266462317000149
Gasol M, Paco N, Guarga L, et al. Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain). J Clin Med. 2022;11(5):1353. Accessed December 18, 2023 DOI: https://doi.org/10.3390/jcm11051353 PMID:35268443 DOI: https://doi.org/10.3390/jcm11051353
Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood. 2023;141(9):971-983. DOI: https://doi.org/10.1182/blood.2022018546 PMID:36399712 DOI: https://doi.org/10.1182/blood.2022018546
Gil-Nagel A, Falip M, Sánchez-Carpintero R, et al. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis. Epilepsy Behav. 2022;132:108711. DOI: https://doi.org/10.1016/j.yebeh.2022.108711 PMID:35588562 DOI: https://doi.org/10.1016/j.yebeh.2022.108711
Abad M, González-Meneses A, Gras E, et al. HTA130 Value Contribution of Olipudase Alfa Therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA). Value Health. 2022;25(12):S321-S322. Accessed February 16, 2023. DOI: https://doi.org/10.1016/j.jval.2022.09.1588 DOI: https://doi.org/10.1016/j.jval.2022.09.1588
Roldán ÚB, Badia X, Marcos-Rodríguez JA, et al. MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING. Int J Technol Assess Health Care. 2018;34(5):519-526. Accessed April 29, 2024. DOI: https://doi.org/10.1017/S0266462318000569 PMID:30348241 DOI: https://doi.org/10.1017/S0266462318000569
ORPHAR-SEFH. Manual para el desarrollo de un informe de evaluación de medicamentos huérfanos por parte del grupo ORPHAR-SEFH usando metodología de Análisis de Decisión Multicriterio. 2020. Online https://gruposdetrabajo.sefh.es/orpharsefh/images/stories/documentos/Manual_MCDA_Orphar_SEFH_060520.pdf (Accessed July 2024)
Orpha-SEFH. Plan_Estratgico_OrPhar-SEFH_2024-2027. Online https://gruposdetrabajo.sefh.es/orpharsefh/images/stories/documentos/Plan_Estratgico_OrPhar-SEFH_2024-2027.pdf (Accessed July 2024)
Álvarez-Román MT, Cuervo-Arango I, Pérez-Santamarina R, et al. Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Glob Reg Health Technol Assess. 2019;6(1):1-8. DOI: https://doi.org/10.1177/2284240319880534 DOI: https://doi.org/10.33393/grhta.2019.452
Domingo C, Fernandez M, Garin N, et al. Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis. Appl Health Econ Health Policy. 2023;21(1):119-130. DOI: https://doi.org/10.1007/s40258-022-00770-9 PMID:36319945 DOI: https://doi.org/10.1007/s40258-022-00770-9
Villanueva V, Carreño M, Gil-Nagel A, et al. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA). Epilepsy Behav. 2021;122:108222. Accessed February 16, 2023. https://pubmed.ncbi.nlm.nih.gov/34371462/ https://doi.org/10.1016/j.yebeh.2021.108222 PMID:34371462 DOI: https://doi.org/10.1016/j.yebeh.2021.108222
Taxonera C, Sala F, Martín I, et al. Determinación de la contribución de valor de filgotinib para el tratamiento de la colitis ulcerosa de moderada a grave mediante el análisis de decisión multicriterio (MCDA). Economía de la Salud. 2023;18(Jul):18. DOI: https://doi.org/10.61679/1803031044 DOI: https://doi.org/10.61679/1803031044
Rao VK, Kulm E, Šedivá A, et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J Allergy Clin Immunol. 2023;0(0). PMID:37797893
Medicines Agency E. Revision 1 Human Medicines Development and Evaluation Benefit-risk methodology project Work package 4 report: Benefit-risk tools and processes Work package 4 report: Benefit-risk tools and processes Report by the EMA Benefit-Risk Methodology Project Team. 2012. Online www.ema.europa.eu (Accessed July 2024)
Health Organization Regional Office for Europe W. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. 2015. Online http://www.euro.who.int/pubrequest (Accessed July 2024)
Thokola P. 2011. Multiple criteria decision analysis (MCDA). REPORT BY THE DECISION SUPPORT UNIT. Online https://www.sheffield.ac.uk/nice-dsu/methods-development/multiple-criteria-decision-analysis (Accessed July 2024)
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2025-01-02
Published 2025-01-27
